Esra Zeynelgil

Dr. Esra Zeynelgil

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2021 in Future Oncology
Verified
Journal Article
Open access
CKCengiz Karacin
Cengiz Karacin
TETülay Eren
Tülay Eren
EZEsra Zeynelgil
Esra Zeynelgil
GİGökşen İnanç İmamoğlu
Gökşen İnanç İmamoğlu
MAMustafa Altinbas
Mustafa Altinbas
BOBerna Oksuzoglu
Berna Oksuzoglu
Aim: To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Methods: This multicenter, prospective, observational study was co... Tweetable abstract Immunogenicity developed with CoronaVac in 25 (59.5%) of 42 patients who received at least one cytotoxic drug and in all patients (n = 5) who received monoclonal antibody or immu...

15 June 2025 in World Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
EZEsra Zeynelgil
Esra Zeynelgil
YDYakup Duzkopru
Yakup Duzkopru
AKAbdulkadir Kocanoglu
Abdulkadir Kocanoglu
SKSerdar Karakaya
Serdar Karakaya
BACKGROUND The hemoglobin-to-red cell distribution width ratio (HRR) is a recently introduced, easily accessible marker that provides insights into inflammation and the tumor vascular microenvironment. It has been suggested to have prognostic value for overall survival in various types of cancer, including urothelial carcinoma, lung cancer, and hepatocellular carcinoma. It has not yet been sufficiently investigated in colorectal cancers (CRC). AIM To investigate the prognostic significance of the HRR and other inflammation-based hematological markers in patients with metastatic CRC. Additionally, the study evaluated the impact of surgical interventions, particularly metastasectomy, and multiple clinical and laboratory parameters on overall survival. By identifying low-cost, accessible prognostic indicators, this research seeks to support clinicians in optimizing treatment strategies and risk stratification for patients with CRC. METHODS In this retrospective study, patients diagnosed with CRC between January 2020 and December 2024 were analyzed. The impact of HRR in conjunction with inflammatory markers and a total of 22 different clinical and laboratory parameters on overall survival were evaluated using univariate Cox regression and a multivariate model. Survival curves were visualized using Kaplan-Meier analysis. RESULTS A total of 155 patients with CRC were included in the study. The median age was 60 years, and 61.9% presented with de novo metastasis. In the receiver operating characteristic curve and area under the curve analysis performed to determine the optimal cutoff, the values were found to be 6.10 for carcinoembryonic antigen (CEA) (P = 0.036), 18.85 for platelet-to-red cell distribution width ratio (P = 0.028), and 10.87 for platelet distribution width-to-lymphocyte ratio (P = 0.028). For neutrophil-to-lymphocyte ratio, systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio, HRR, and carbohydrate antigen 19-9, an optimal cutoff could not be determined using the receiver operating characteristic-area under the curve analysis. Therefore, the median values were adopted as the cutoffs (3.09, 835.96, 177.50, 0.380, 0.824, and 21.6, respectively). Univariate analysis identified male gender (P = 0.045), being under 65 years of age (P = 0.001), history of metastasectomy (P = 0.001), low serum CEA level (P = 0.010), low PLR (P = 0.024), low SII (P = 0.010), and high HRR (P = 0.025) as favorable prognostic factors for overall survival. In the multivariate model, being under 65 years of age [hazard ratio (HR) = 1.59, 95% confidence interval (CI): 1.06-2.39, P = 0.025], metastasectomy (HR = 0.49, 95%CI: 0.29-0.85, P = 0.011), CEA (HR = 1.51, 95%CI: 1.0-2.28, P = 0.048), and PLR (HR = 1.63, 95%CI: 1.09-2.44, P = 0.018) emerged as independent prognostic factors for overall survival, whereas gender, SII, and HRR did not retain statistical significance. CONCLUSION In conclusion, low HRR alone was a prognostic indicator. However, when modelled with other inflammatory and clinical parameters, it did not provide a sufficiently strong marker feature.

1 November 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
EZEsra Zeynelgil
Esra Zeynelgil
DÇDilek Çağlayan
Dilek Çağlayan
SÇSelahattin Çelik
Selahattin Çelik
HSHatice Ayyıldız Sevim
Hatice Ayyıldız Sevim
HŞHayriye Şahinli
Hayriye Şahinli
TETülay Eren
Tülay Eren
Objective: To investigate the prognostic value of clinical and inflammatory markers predicting response to nivolumab in patients with metastatic non-small cell lung cancer (NSCLC). Materials and Methods: Clinical, demographic and laboratory data of stage 4 NSCLC patients who were treated between February 2021 and November 2024 were analyzed. Before nivolumab treatment, inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), prognostic nutritional index (PNI), hemoglobin-albumin-lymphocyte-platelet score (HALP), neutrophil-to-eosinophil ratio (NER) and C-reactive protein-to-albumin ratio (CAR) were calculated. Factors affecting overall survival (OS) were determined by Cox regression analysis, and ROC curve analysis was used to calculate the ideal cut-off. Results: The study included 229 NSCLC patients and the median age of the patients was 63 years. The majority were male (84.3%) and had right lung localization (56.8%). Median overall survival was calculated as 21.2 months (95% CI: 17.4– 25.0). In univariate cox-regression analysis, the presence of brain metastases (HR: 2.08; p=0.004), liver metastases (HR: 1.85; p=0.014) and adrenal metastases (HR: 1.64; p=0.045) negatively affected the treatment response. Inflammatory markers such as high NLR (HR: 2.04; p< 0.001), high SII (HR: 1.96; p< 0.001), high CAR (HR: 1.84; p=0.001), high PLR (HR: 1.60; p=0.009) and high SIRI (HR: 1.51; p=0.021), low PNI (HR: 0.48; p< 0.001), low HALP (HR: 0.49; p< 0.001) and low LMR (HR: 0.65; p=0.016) were associated with poor prognosis. In multivariate analysis, the presence of brain metastasis (HR: 2.84; p< 0.001), adrenal metastasis (HR: 1.64; p=0.046) and low PNI (HR: 0.44; p< 0.001) together predicted poor prognosis and formed a statistical model on treatment response. Conclusion: In patients with metastatic NSCLC, nivolumab treatment response is predicted by inflammatory markers and the presence of brain and adrenal metastases. It was concluded that low PNI among inflammatory markers is a strong prognostic indicator in this patient group.

27 May 2025 in Medicina
Verified
Journal Article
Open access
PDF file
AKAbdülkadir Koçanoğlu
Abdülkadir Koçanoğlu
SKSerdar Karakaya
Serdar Karakaya
EZEsra Zeynelgil
Esra Zeynelgil
YDYakup Duzkopru
Yakup Duzkopru
ODozlem dogan
ozlem dogan
Background and Objectives: This study aimed to investigate the prognostic value of the hemoglobin–albumin–lymphocyte–platelet (HALP) score—a marker reflecting both inflammatory and nutritional status—in patients with metastatic non-small cell lung cancer (NSCLC) undergoing immunotherapy. We also sought to determine whether dynamic changes in the HALP score during treatment could predict therapeutic success and help distinguish between pseudoprogression and hyperprogression. Materials and Methods: A retrospective analysis was conducted on 160 patients diagnosed with metastatic NSCLC and treated with immunotherapy at the Ankara Atatürk Sanatorium Training and Research Hospital. Chemotherapy regimens, metastatic sites, baseline and third-month hemograms and biochemistry parameters, and survival data were recorded. Survival outcomes were analyzed using the Kaplan–Meier method with the log-rank test and the Cox proportional hazards regression model using IBM SPSS Statistics. Results: The median overall survival (OS) for the entire cohort was 15 months (95% CI: 11.88–18.12). HALP1 score (p = 0.048), HALP2 score (p = 0.026), and hyperprogression (p < 0.001) were statistically significant predictors of OS. Regarding progression-free survival (PFS), the HALP2 score (p = 0.031), line of immunotherapy (p = 0.046), and hyperprogression (p < 0.001) were found to be significant. When comparing patients with increasing versus decreasing HALP scores, those with increasing HALP scores demonstrated significantly better outcomes for both OS (p = 0.034) and PFS (p = 0.007). Conclusions: In patients with metastatic NSCLC undergoing immunotherapy, the HALP score and its dynamic alterations during treatment appear to be non-invasive, easily calculable biomarkers that may predict both OS and PFS.

16 January 2025 in Medicina
Verified
Journal Article
Open access
PDF file
NSnadiye sever
nadiye sever
SYSEDAT YILDIRIM
SEDAT YILDIRIM
AGAli Fuat Gurbuz
Ali Fuat Gurbuz
DKDELYADIL KARAKAŞ KILIÇ
DELYADIL KARAKAŞ KILIÇ
EZEsra Zeynelgil
Esra Zeynelgil
İBİbrahim Vedat Bayoğlu
İbrahim Vedat Bayoğlu
Background and Objectives: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with a poor prognosis. Identifying reliable prognostic factors is crucial for risk stratification and optimizing treatment strategies. This study aimed to evaluate the impact of clinicopathologic factors and systemic inflammatory markers on survival outcomes in patients with MPM. Materials and Methods: This retrospective, multicenter study included 217 patients diagnosed with MPM between January 2009 and March 2024. Data on age, gender, histology, disease stage, treatment modalities, and inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein/albumin ratio (CAR) were collected. Survival outcomes were analyzed using Kaplan–Meier methods, and prognostic factors were evaluated using Cox regression analysis. Results: CAR was identified as an independent prognostic factor for both overall survival (OS) and progression-free survival (PFS). Patients with CAR < 0.98 had significantly longer OS (87.0 months vs. 14.0 months, p < 0.001) and PFS (17.61 months vs. 8.96 months, p = 0.010). While NLR was significant in univariate analysis (OS: 25.0 months for NLR < 2.58 vs. 21.0 months for NLR ≥ 2.58, p = 0.040), it did not retain significance in the multivariate model (p = 0.180). Epithelioid histology and early-stage disease were strongly associated with improved survival outcomes (OS: 32.0 vs. 11.0 months for epithelioid vs. non-epithelioid histology, p < 0.001; 32.0 vs. 12.0 months for early-stage vs. metastatic disease, p < 0.001). Conclusions: CAR is a strong independent prognostic factor in MPM, reflecting systemic inflammation and nutritional status. Epithelioid histology and early-stage disease are associated with significantly longer survival, underscoring the critical role of early detection in improving patient outcomes.

30 June 2023 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Open access
EZEsra Zeynelgil
Esra Zeynelgil
ÖDÖzlem Doğan
Özlem Doğan
BSBuğra Sağlam
Buğra Sağlam
MAMEHMET ASIL
MEHMET ASIL
Amaç: Çalışmamızda farklı hematolojik maligniteleri olan hasta gruplarında tanı anındaki serum siyanokobalamin (Vitamin B12) düzeylerinin tanıları ön görmede etkisini araştırmayı planladık.. Gereç ve Yöntemler: Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi Hematoloji poliklinik ve kliniğine 2010-2014 yılları arasında başvurmuş olan 18-75 yaş arası hematolojik malignite tanısı almış olan 201 hasta ve 30 sağlıklı kontrol grubu çalışma kapsamına alındı. Çalışma kapsamına dahil edilen hastaların demografik, klinik ve laboratuar verileri retrospektif olarak kayıt altına alınmıştır. Bulgular: Çalışmamıza 132’si erkek (%57,1) ve 99’u kadın (%42,9) olmak üzere toplam 201 hasta ve 30 sağlıklı kontrol grubu olmak üzere 231 kişi dahil edildi. Tüm hastaların ortalama serum Vitamin B12 konsantrasyonu 344,9±279,0 pg/mL olarak gözlendi. Tanı gruplarına göre Vitamin B12 düzeylerinin değerlendirmesinde ise; KML (596,0±428,3 pg/mL) ve ALL (524,5±442,6 pg/mL) hastalarında en yüksek, AML (240,9±178,0 pg/mL) hastalarında ise en düşük olduğu ve bu farklılığın istatistiksel olarak anlamlı olduğu gözlendi (p<0,001). Hastalık gruplarının Vitamin B12 düzeylerinin sağ kalım üzerine anlamlı fark saptanmamıştır. Sonuç: Hematolojik malignitesi olan hastalarda ve özellikle KML hastalarında siyanokobalamin düzeyi yüksek bulunmuştur. KML hastalığının tanısı için yüksek siyanokobalamin düzeyi hastalığı ön görmede yardımcı olabilir ancak bunun prospektif çalışmalarla deseklenmesi gerekmektedir. Anahtar Kelimeler: siyanokobalamin, KML, ALL,AML, Vitamin B12 ABSTRACT Aim: In our study, we planned to investigate the effect of serum cyanocobalamin (Vitamin B12) levels at the time of diagnosis in patients with various hematological malignancies. Patients and Methods: Two hundred and one patients between 18-75 years old diagnosed with various hematological malignancies and 30 healthy controls applying to outpatient and inpatient clinics of Hematology Department in Necmettin Erbakan University Meram Faculty of Medicine between 2010-2014 years were included in the study. Demographic and clinical data and laboratory findings of the patients included in the study were recorded retrospectively. Results: A total of 231 patients, 132 men (57.1%) and 99 women (42.9%), were included in our study, of which 201 were patients and 30 were healthy controls. The mean serum vitamin B12 concentration of all patients was found as 344.9 ± 279.0 pg/mL. When vitamin B12 levels were analyzed according to diagnostic groups, it was found to be highest in CML (596.0 ± 428.3 pg / mL) and ALL (524.5 ± 442.6 pg / mL) patients and lowest in AML patients (240.9 ± 178, 0 pg / mL); the difference was statistically significant (p <0.001). Vitamin B12 levels of diagnostic groups were found to have no significant effect on survival. Conclusion: Cyanocobalamin levels were found to be high in patients with hematological malignancies, especially in CML patients. A high level of cyanocobalamin may be helpful in prediction of CML, however prospective studies are required to support this finding.